Use of B‐natriuretic peptide as a diagnostic marker in the differential diagnosis of transfusion‐associated circulatory overload
- 29 June 2005
- journal article
- research article
- Published by Wiley in Transfusion
- Vol. 45 (7) , 1056-1063
- https://doi.org/10.1111/j.1537-2995.2005.04326.x
Abstract
BACKGROUND: Transfusion‐associated circulatory overload (TACO) occurs when the transfusion rate or volume exceeds the capacity of a compromised cardiovascular system. Characteristic symptoms and signs associated with TACO are neither sensitive nor specific. B‐natriuretic peptide (BNP) is a 32‐amino‐acid polypeptide secreted from the cardiac ventricles in response to ventricular volume expansion and pressure overload. This study was performed to explore the usage of BNP in the differential diagnosis of TACO.STUDY DESIGN AND METHODS: Pre‐ and posttransfusion BNP levels were determined in 21 patients with suspected TACO and 19 control patients. The BNP was considered significant if the posttransfusion‐to‐pretransfusion ratio was at least 1.5 and the posttransfusion BNP level was at least 100 pg per mL.RESULTS: The BNP test has a sensitivity and specificity of 81 and 89 percent, respectively, in diagnosis of TACO. It has a positive predictive value of 89 percent, a negative predictive value of 81 percent, and an accuracy of 87 percent. In logistic regression analysis, BNP was found to have significant predictive power independent of other clinical variables in models predicting which patients had TACO.CONCLUSIONS: Our study suggests that in patients who present symptoms suggestive of TACO, BNP can be a useful adjunct marker in confirming volume overload as the cause of acute dyspnea and symptoms related to cardiovascular compromise.Keywords
This publication has 26 references indexed in Scilit:
- Toward an understanding of transfusion‐related acute lung injury: statement of a consensus panelTransfusion, 2004
- Use of brain natriuretic peptide to evaluate transfusion‐related acute lung injuryTransfusion, 2004
- An unusual plasmapheresis productTransfusion, 2003
- Transfusion-Related Acute Lung InjuryJAMA, 2002
- Immunoreactive amino‐terminal pro‐brain natriuretic peptide (NT‐PROBNP): a new marker of cardiac impairmentClinical Endocrinology, 1997
- Superiority of Brain Natriuretic Peptide as a Hormonal Marker of Ventricular Systolic and Diastolic Dysfunction and Ventricular HypertrophyHypertension, 1996
- Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload.Journal of Clinical Investigation, 1995
- Plasma brain natriuretic peptide in assessment of acute dyspnoeaThe Lancet, 1994
- Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal manJournal of Clinical Endocrinology & Metabolism, 1993
- Reports of 355 transfusion‐associated deaths: 1976 through 1985Transfusion, 1990